AI SDR agents for Series A companies: the 90-day install for healthcare and life sciences in the United Kingdom
The exact 90-day plan for standing up AI SDR agents at Series A — the point where the founder can no longer be every function. Written for commercial leaders at healthtech, medtech, and life-sciences companies in the United Kingdom.
This edition of the Growth Broker playbook is written for commercial leaders at healthtech, medtech, and life-sciences companies operating in the United Kingdom. In this market, UK buyers reward understatement, credible references, and a pitch that respects their time, so the way you install AI SDR agents has to be shaped to that reality from day one.
Series A is the moment AI SDR agents stops being optional. The founder has to step out of some of the work, the plan requires a defensible growth number, and every quarter compounds toward the next raise.
Day 1 to 30: diagnosis and instrumentation. Name the constraint, write the ICP, wire qualified meetings per $1k of AI spend per week into the board pack.
Day 31 to 60: first live cycle at 20% of planned volume. Founder still in every review. Kill criteria written and enforced.
Inside healthcare and life sciences, the binding constraint is almost always regulated-sale cycle length, not intent, and in the United Kingdom it is compounded by the fact that credibility and reference base, not tooling is what actually gates growth. AI SDR agents is only useful here when it is pointed at both constraints at once.
Day 61 to 90: ramp to full volume, hire the first dedicated operator, and hand off ops. Founder retains strategy and the weekly review.
By day 90 the metric is legible and the trajectory is defensible. This is what turns a Series A story into a Series B round.
Trap most Series A companies fall into: spraying generic sequences from an unwarmed domain and burning sender reputation. It usually shows up around day 45 when the founder tries to hire ahead of the model.
The Series A version of AI SDR agents looks small compared to what you will build at Series B. That is the point — it is a foundation, not a monument.
Concretely for healthcare and life sciences in the United Kingdom: the healthcare teams that install this get past procurement instead of dying in it, and a single London-anchored win reshapes an entire year of UK pipeline. That is the reason it is worth installing AI SDR agents deliberately for this market rather than importing a playbook designed for somewhere else.
Frequently asked questions
AI Outreach · healthcare · UK — answered
- Does AI SDR agents work for healthcare and life sciences in the United Kingdom?
- Yes — provided it is pointed at regulated-sale cycle length, not intent and adapted to the fact that in the United Kingdom, UK buyers reward understatement, credible references, and a pitch that respects their time. The healthcare teams that install this get past procurement instead of dying in it.
- Should we start AI SDR agents before Series A?
- Yes if the founder has time; the Series A version is the same model at higher spend.
- How much of the round should fund AI SDR agents?
- Meaningful — often 20–30% of the growth line — but only after diagnosis.
- When do we hire the first AI SDR agents operator?
- Around day 60, once the model has run one full cycle with the founder.
- What Series A trap should we avoid?
- Spraying generic sequences from an unwarmed domain and burning sender reputation — usually a premature senior hire.
- What is the UK-specific pitfall when running AI SDR agents for healthcare?
- Importing a playbook that was built for another market. In the United Kingdom, UK buyers reward understatement, credible references, and a pitch that respects their time — the install has to reflect that.
Growth Broker editorial
Filed under ai outreach · healthcare · uk